What is the official ID of this bill?

The official print number for this legislation is HR 4215.

When did the legislative process begin?

The process officially started on 2023-06-20.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/hr4215/BILLS-118hr4215ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Who is the primary sponsor?

The primary sponsor is Rep. Dingell, Debbie [D-MI-6].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HR 4215

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

End Drug Price Gouging: Lower Medication Costs for Federal Programs

Q: What are the main provisions?

Key points include: Setting maximum prescription drug prices based on prices in developed countries like Japan or Germany. Lower drug prices for individuals covered by Medicare, Medicaid, TRICARE, veterans' and federal employee programs, and for Native Americans. Drug manufacturers will be required to offer drugs at these lower prices to uninsured individuals and those with private health plans. Financial penalties for manufacturers who do not comply, with collected funds directed towards drug research and development.

This bill aims to lower prescription drug prices in the United States. It establishes maximum drug prices based on prices in other developed countries. As a result, citizens covered by federal health programs, as well as uninsured individuals, can expect lower medication costs.

Key points

Setting maximum prescription drug prices based on prices in developed countries like Japan or Germany.

Lower drug prices for individuals covered by Medicare, Medicaid, TRICARE, veterans' and federal employee programs, and for Native Americans.

Drug manufacturers will be required to offer drugs at these lower prices to uninsured individuals and those with private health plans.

Financial penalties for manufacturers who do not comply, with collected funds directed towards drug research and development.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

End Price Gouging for Medications Act

Print number: HR 4215

Sponsor: Rep. Dingell, Debbie [D-MI-6]

Process start date: 2023-06-20

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

End Drug Price Gouging: Lower Medication Costs for Federal Programs

Key Questions about End Drug Price Gouging: Lower Medication Costs for Federal Programs